Evotec, Bristol Myers Squibb secure second FDA IND clearance in protein degradation partnership
EVO•Evotec and Bristol Myers Squibb secured FDA clearance for a second investigational drug under their protein-degradation partnership. The molecular glue drug candidate is expected to enter a Phase 1 trial in 2027.
1. Second drug cleared
Evotec and Bristol Myers Squibb secured FDA clearance for a second investigational drug under their protein-degradation partnership. The molecular glue drug candidate is expected to enter a Phase 1 trial in 2027.




